A Study of YL201 in Patients With Advanced Solid Tumors
A phase 1/2 trial of YL201 and Atezolizumab in advanced solid tumours, run by MediLink Therapeutics (Suzhou) Co., Ltd., now recruiting.
Overview
A Study of YL201 in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05434234 by MediLink Therapeutics (Suzhou) Co., Ltd., with 312 participants planned, started 2022-05-25 and due to reach its primary completion in 2027-04-06. Interventions recorded: YL201 and YL201 and atezolizumab.
Similar pages
not linked directly; found by shared links- TrialA Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors
Shares YL201, Atezolizumab and the tag pipeline.
- TrialA Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)
Shares Atezolizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialAn Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)
Shares Atezolizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialInvestigation of a Therapeutic Vaccine (ACIT-1) in Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPlasmodium Immunotherapy for Advanced Malignant Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialFirst-in-Human Study of ICT01 in Patients With Advanced Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPhase 1/2a Study of MPB-1734 in Patients With Advanced Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.